分化型甲状腺癌甲状腺CT诊断率按治疗反应分层的结果
回顾性纳入450例全甲状腺切除及放射性碘消融后行甲状腺CT的分化型甲状腺癌患者,按美国甲状腺学会指南分为疗效满意、生化不全、意义不明和结构不全反应组。甲状腺CT总体诊断率为15.3%,疗效满意组2%、生化不全组23.1%、意义不明组26.9%;意义不明组中超声阴性者诊断率7.5%,低于超声意义不明病灶者的44.2%(p < 0.001)。
要点
- 甲状腺CT总体诊断率为15.3%(69/450;95%CI:12.3-19%)。
- 疗效满意组诊断率2%(4/201;95%CI:0.6-5.2%),低于生化不全组23.1%(12/52;95%CI:13.6-36.3%)和意义不明组26.9%(53/197;95%CI:21.2-33.5%)。
- 意义不明组中超声阴性者诊断率7.5%(7/93;95%CI:3.5-15%),低于超声意义不明病灶者44.2%(46/104;95%CI:35.1-53.8%)(p < 0.001)。
核心结论
- 甲状腺CT诊断率随治疗反应不同而异,疗效满意组和超声阴性的意义不明组较低,生化不全组和超声有意义不明病灶的意义不明组较高。
研究设计与样本
- 回顾性研究,纳入450例全甲状腺切除及放射性碘消融后行甲状腺CT的分化型甲状腺癌患者(平均年龄44.9±13.4岁;164例男性),按美国甲状腺学会指南分为疗效满意、生化不全、意义不明和结构不全反应组,采用卡方检验及Bonferroni校正比较组间诊断率。
诊断标准与关键数值
- 诊断率定义为全部患者中复发肿瘤患者的比例。
- 总体诊断率15.3%(69/450;95%CI:12.3-19%)。
- 疗效满意组诊断率2%(4/201;95%CI:0.6-5.2%)。
- 生化不全组诊断率23.1%(12/52;95%CI:13.6-36.3%)。
- 意义不明组诊断率26.9%(53/197;95%CI:21.2-33.5%);其中超声阴性者7.5%(7/93;95%CI:3.5-15%),超声意义不明病灶者44.2%(46/104;95%CI:35.1-53.8%)(p < 0.001)。
临床应用与阅片要点
- 作者指出,依据治疗反应使用CT可能提高复发肿瘤检出或澄清超声不明确的发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the diagnostic yield of thyroid CT in patients with post-treatment differentiated thyroid carcinoma (DTC) stratified by treatment response.
MATERIALS AND METHODS: This retrospective study included DTC patients who underwent total thyroidectomy and radioactive iodine ablation, followed by thyroid CT. Patients were categorized into response assessment groups according to the American Thyroid Association guidelines: excellent response (ER), biochemical incomplete response (BIR), indeterminate response (IR), and structural incomplete response (SIR). Diagnostic yield was defined as the proportion of patients with recurrent tumors among all patients. The yields of ER, BIR, and IR were compared. For IR, subgroup analyses were performed based on the presence of indeterminate lesions on ultrasound (US). Chi-squared tests with Bonferroni correction were used to compare the diagnostic yields between groups.
RESULTS: A total of 450 patients (mean age, 44.9 ± 13.4 years; 164 men) were included. The overall diagnostic yield of thyroid CT was 15.3% (69/450; 95% confidence interval [CI]: 12.3-19%). Yields for the ER, BIR, and IR groups were 2% (4/201; 95% CI: 0.6-5.2%), 23.1% (12/52; 95% CI: 13.6-36.3%), and 26.9% (53/197; 95% CI: 21.2-33.5%), respectively. Among IR patients, the yield was significantly lower in US-negative patients (7.5%, 7/93; 95% CI: 3.5-15%) compared to those with indeterminate US lesions (44.2%, 46/104; 95% CI: 35.1-53.8%) (p < 0.001).
CONCLUSION: The diagnostic yield of thyroid CT varies according to the treatment response; it was low in ER and US-negative IR but higher in BIR and IR with indeterminate US lesions.
KEY POINTS: Question Guidelines recommend considering CT for follow-up in DTC based on treatment response, but the diagnostic yield of CT remains underexplored. Findings The diagnostic yield of CT was low in an ER and US-negative IR but higher in BIR and US-positive IR. Clinical relevance The diagnostic yield of thyroid CT varies according to treatment response. Utilizing CT based on treatment response may enhance the detection of recurrent tumors or clarify unclear findings on US.
引用
- Roh YH, Chung SR, Baek JH, et al. Diagnostic yield of thyroid CT in differentiated thyroid carcinoma according to treatment response. Eur Radiol. 2025. PMID: 40285816. doi:10.1007/s00330-025-11613-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。